Fouzia Laghrissi-Thode, has more than 20 years of pharmaceutical industry leadership experience including leading the Dalcetrapib Dal-HEART program. Most recently, Dr. Laghrissi-Thode was Vice-President at AstraZeneca of the US Renal-Cardiology Therapeutic Area. Her previous roles include Head of the Cardiovascular and Metabolism Therapeutic Area, Global Product and Portfolio Strategy at AstraZeneca and Roche. She has a wealth of experience in US and Europe through working in clinical development, global strategic marketing, business development, licensing and M&A in a variety of therapeutic areas including cardiovascular, diabetes, renal and the central nervous system. She has served as a board member of the Healthcare Businesswomen’s Association (HBA) Europe and was recognized by HBA in 2012 for her work in developing and promoting women leadership in healthcare. She was a faculty member at the University of Pittsburgh Medical Center (UPMC) Western Psychiatric Institute and Clinic (WPIC), is board certified in Psychiatry (Limoges, France). Dr. Laghrissi-Thode holds Doctorate in Medicine (MD) from the University of Tours School of Medicine in France.
Donald M. Black has over 25 years of experience, during which he has held various senior leadership positions working in clinical development. Dr. Black served as general manager of advanced diabetes care at Becton Dickinson, global leader of research and development as well as general manager of molecular imaging at GE Medical Diagnostics, vice president of global strategic development at Merck and Co, and vice president of clinical research at Parke-Davis from 1990 to 2000, where he was responsible for the clinical development of Lipitor.
As the chief medical officer at DalCor, he is responsible for clinical and regulatory activities in the development of dalcetrapib.
Dr. Black has served on multiple boards of directors as well as scientific boards, and has over 150 publications, presentations and chapters. His academic appointments include associate professor of pediatric cardiology at the University of Michigan, professor of medicine at the University of Cincinnati, and adjunct professor of medicine, National University of Ireland at Galway.
Dr. Black has earned his M.D. from University of Michigan Medical School and his MBA University of Cincinnati College of Business.
Louise Proulx is an industry veteran with 30 years of experience in the pharmaceutical industry and has held scientific and managerial positions of increasing responsibilities. Notably, Dr. Proulx was vice president of scientific affairs at Hoechst Marion Roussel Canada, vice president of therapeutic product development at BioChem Pharma Inc., vice president of business development of Genome Quebec and vice principal of research at McGill University. She has been vice president of product development at ViroChem Pharma Inc., and vice president and site head at Vertex Pharmaceuticals (Canada) Incorporated after the acquisition of ViroChem Pharma by Vertex Pharmaceuticals.
As chief development officer at DalCor, Dr. Proulx oversees the development of dalcetrapib. Louise is also chief development officer at Therillia.
Dr. Proulx has been a member of several boards of directors and is a member of the board of directors of the Research Institute of McGill University Health Center, Gestion Univalor, Verlyx Pharma and CQDM. Dr. Proulx is certified ICD.D by the Institute of Corporate Directors. She is also member of the Canada Foundation for Innovation.
Michael Dixon, has over 18 years of experience working in an executive role for venture-backed companies. At DalCor, Mr. Dixon oversees all financial, legal and administrative matters, and is also president and chief executive officer at Therillia.
Mr. Dixon was chief financial officer of Gemin X Pharmaceuticals. At Gemin X he structured and negotiated equity financings leveraged with venture debt and other forms of non-dilutive capital to fund the company’s Canadian and US operations over an 11-year period. Gemin X was successfully sold to Cephalon (now Teva), at the time one of the largest private biotech deals in Canada.
Prior to Gemin X, Mr. Dixon was Interim COO and vice president of finance at Morphometrix Technologies, a medical device company specialized in the automation of cervical cancer screening.
Mr. Dixon began his career at Price Waterhouse with a focus on compliance services for entrepreneurial businesses, strategic financial modeling and management information systems. Mr. Dixon received his Bachelor of Commerce degree from the University of Toronto and his Chartered Accountant designation while at Price Waterhouse.
Bruno Pirovino-Zuercher has more than 20 year of experience in both managing and consulting start-up and matured pharmaceutical companies.
Mr Pirovino-Zürcher is director at the Swiss branch of DalCor and oversees all aspects the development of dalcetrapib.
His international career path encompassed several years in accounting, finance, business and management roles at IMS Health, Pliva International, Eisai Pharmaceuticals and Johnson & Johnson.
He holds a Bachelor’s degree in Business Administration and an Executive Master’s degree in Corporate Finance from the Lucerne University of Applied Sciences and Arts as well as a CAS in Global Entrepreneurship gained at the University of Basel / Switzerland.
A graduate of Michigan State University College of Veterinary Medicine, Dr. Heinonen has an active interest in the evaluation of potential cardiovascular biomarkers and their appropriate application in clinical trials. She received training in molecular biology at Merck Research Laboratories, and was a member of the Pfizer Global Research and Development cardiovascular senior management team where she made significant contributions to the clinical development of Lipitor. Dr. Heinonen has accumulated over 27 total years of research experience, with 25 years dedicated to clinical research in the areas of cardiology, endocrinology, neurology, and oncology. Additional areas of interest include utilizing traditional and innovative medical strategies to improve upon clinical trial design and methodology. Dr. Heinonen has authored over 50 publications and managed over 30 clinical trials, many of which have focused on cardiovascular biomarkers and imaging technologies. Dr. Heinonen has worked as a consultant to government institutions, academic institutions, pharmaceutical companies, biotechnology organizations and diagnostic companies. In 2003, Dr. Heinonen began organizing the annual Cardiovascular Biomarkers and Surrogate Endpoints Symposium and in 2006 co-founded the International Partnership for Critical Markers of Disease. Dr. Heinonen has also founded or significantly contributed to the initiation of several start-up companies.